Literature DB >> 22067201

The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis.

Samuel B Keller, Davey M Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22067201      PMCID： PMC3874210          DOI： 10.1097/QAD.0b013e32834d3cab

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  9 in total

1.  Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-01-28       Impact factor: 17.586

2.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

3.  How much are Americans willing to pay for a quality-adjusted life year?

Authors:  Milton C Weinstein
Journal:  Med Care       Date:  2008-04       Impact factor: 2.983

4.  Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policy.

Authors:  Rochelle P Walensky
Journal:  Top HIV Med       Date:  2009 Sep-Oct

5.  Preexposure chemoprophylaxis for HIV prevention.

Authors:  Dong Heun Lee; Ole Vielemeyer
Journal:  N Engl J Med       Date:  2011-04-07       Impact factor: 91.245

6.  The cost effectiveness of combination antiretroviral therapy for HIV disease.

Authors:  K A Freedberg; E Losina; M C Weinstein; A D Paltiel; C J Cohen; G R Seage; D E Craven; H Zhang; A D Kimmel; S J Goldie
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

7.  The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.

Authors:  Elisa F Long; Margaret L Brandeau; Douglas K Owens
Journal:  Ann Intern Med       Date:  2010-12-21       Impact factor: 25.391

8.  Recent decline in the incidence of human immunodeficiency virus infection among California men who have sex with men.

Authors:  Qiang Xia; Atsuko Nonoyama; Fred Molitor; David Webb; Dennis Osmond
Journal:  Am J Epidemiol       Date:  2011-05-17       Impact factor: 4.897

9.  HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.

Authors:  A David Paltiel; Kenneth A Freedberg; Callie A Scott; Bruce R Schackman; Elena Losina; Bingxia Wang; George R Seage; Caroline E Sloan; Paul E Sax; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079
  9 in total
  12 in total

Review 1.  Plasmacytoid dendritic cells in HIV infection.

Authors:  Meagan O'Brien; Olivier Manches; Nina Bhardwaj
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

2.  Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.

Authors:  Kristen Underhill
Journal:  Am J Law Med       Date:  2012

Review 3.  Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US.

Authors:  Fred J Hellinger
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

4.  The Price of Prevention: Cost Effectiveness of Biomedical HIV Prevention Strategies in South Africa.

Authors:  Nishila Moodley; Glenda Gray; Melanie Bertram
Journal:  Clin Res HIV AIDS       Date:  2016-11-27

5.  Oral PrEP for HIV prevention. It works.

Authors:  Erica Pool; Elaney Youssef; Martin Fisher
Journal:  J Virus Erad       Date:  2015-07-01

6.  Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.

Authors:  Heun Choi; Jiyeon Suh; Woonji Lee; Jun Hyoung Kim; Jung Ho Kim; Hye Seong; Jin Young Ahn; Su Jin Jeong; Nam Su Ku; Yoon Soo Park; Joon Sup Yeom; Changsoo Kim; Hee-Dae Kwon; Davey M Smith; Jeehyun Lee; Jun Yong Choi
Journal:  Sci Rep       Date:  2020-09-03       Impact factor: 4.379

Review 7.  The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.

Authors:  Gabriela B Gomez; Annick Borquez; Kelsey K Case; Ana Wheelock; Anna Vassall; Catherine Hankins
Journal:  PLoS Med       Date:  2013-03-12       Impact factor: 11.069

8.  Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs.

Authors:  Panita Maturavongsadit; Roopali Shrivastava; Craig Sykes; Mackenzie L Cottrell; Stephanie A Montgomery; Angela D M Kashuba; S Rahima Benhabbour
Journal:  Int J Pharm       Date:  2021-07-01       Impact factor: 6.510

9.  Mathematical modeling of HIV prevention measures including pre-exposure prophylaxis on HIV incidence in South Korea.

Authors:  Sun Bean Kim; Myoungho Yoon; Nam Su Ku; Min Hyung Kim; Je Eun Song; Jin Young Ahn; Su Jin Jeong; Changsoo Kim; Hee-Dae Kwon; Jeehyun Lee; Davey M Smith; Jun Yong Choi
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

10.  Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes.

Authors:  Sulav Duwal; Laura Dickinson; Saye Khoo; Max von Kleist
Journal:  PLoS Comput Biol       Date:  2018-06-14       Impact factor: 4.475
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.